Clinical Trials Logo

Clinical Trial Summary

IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure. Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06279715
Study type Observational
Source Clinique Ovo
Contact
Status Active, not recruiting
Phase
Start date January 19, 2024
Completion date February 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT04574310 - Does the Air-bubble Location Influence on the Implantation Rate
Completed NCT03354013 - Genetic Screening and Assisted Oocyte Activation in Couples With Diminished/Aberrant Embryonic Development. N/A
Not yet recruiting NCT04734769 - Embryos With Preimplantation Genetic Testing for Aneuploidies (PGT-A) Inconclusive Result: Clinical Implications
Recruiting NCT04736160 - Pilot Study: hCG Secreted by Blastocyst as Potential Marker of Embryo Quality